A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 10, 2011, Pages 2029-2037

  Hosokawa, K ^a,b   Ohnishi, T ^a   Kondo, T ^a   Fukasawa, M ^a   Koide, T ^c   Maruyama, I ^b   Tanaka, K A ^d  

^a Fujimori Kogyo CO   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c UNIVERSITY OF HYOGO   (Japan)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coagulation; Microchip flow chamber; Platelet activation; Shear rate; Thrombus formation

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ARGATROBAN; ENOXAPARIN; FIBRIN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN IB ALPHA ANTAGONIST; HEPARIN; OS 1; THROMBIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD EXAMINATION; BLOOD FLOW; BLOOD VESSEL OCCLUSION; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; FEMALE; HUMAN; MALE; MICROCHIP ANALYSIS; MICROCHIP FLOW CHAMBER SYSTEM; NORMAL HUMAN; PARTICLE SIZE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SHEAR RATE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOELASTOMETRY; THROMBOGENESIS; TIME; WHITE THROMBUS FORMATION;

ADULT; AUTOMATION; BLOOD CIRCULATION; BLOTTING, WESTERN; FEMALE; HUMANS; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 80053390777     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04464.x     Document Type: Article

References (35)

1. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
2. Rentrop KP. Thrombi in acute coronary syndromes: revisited and revised. Circulation 2000; 101: 1619-26.
3. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94: 2013-20.
4. Fogelson AL, Tania N. Coagulation under flow: the influence of flow-mediated transport on the initiation and inhibition of coagulation. Pathophysiol Haemost Thromb 2005; 34: 91-108.
5. Kawasaki J, Katori N, Kodaka M, Miyao H, Tanaka KA. Electron microscopic evaluations of clot morphology during thrombelastography. Anesth Analg 2004; 99: 1440-4.
6. Hanson SR, Sakariassen KS. Blood flow and antithrombotic drug effects. Am Heart J 1998; 135: S132-45.
7. Weiss HJ, Turitto VT, Baumgartner HR. Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoproteins IIb-IIIa, Ib, and storage granules. Blood 1986; 67: 322-30.
8. Weiss HJ, Turitto VT, Baumgartner HR. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelet defects. J Clin Invest 1986; 78: 1072-82.
9. Sakariassen KS, Joss R, Muggli R, Kuhn H, Tschopp TB, Sage H, Baumgartner HR. Collagen type III induced ex vivo thrombogenesis in humans. Role of platelets and leukocytes in deposition of fibrin. Arteriosclerosis 1990; 10: 276-84.
10. Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009; 119: 2625-32.
11. Harle CC. Point-of-care platelet function testing. Semin Cardiothorac Vasc Anesth 2007; 11: 247-51.
12. Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008; 106: 1366-75.
13. Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5: 886-8.
14. Swartz MJ, Mitchell HL, Cox DJ, Reeck GR. Isolation and characterization of trypsin inhibitor from opaque-2 corn seeds. J Biol Chem 1977; 252: 8105-7.
15. Benard SA, Smith TM, Cunningham K, Jacob J, DeSilva T, Lin L, Shaw GD, Kriz R, Kelleher KS. Identification of peptide antagonists to glycoprotein Ibalpha that selectively inhibit von Willebrand factor dependent platelet aggregation. Biochemistry 2008; 47: 4674-82.
16. Lev EI, Hasdai D, Scapa E, Tobar A, Assali A, Lahav J, Battler A, Badimon JJ, Kornowski R. Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation. J Am Coll Cardiol 2004; 43: 966-71.
17. Sarich TC, Osende JI, Eriksson UG, Fager GB, Eriksson-Lepkowska M, Ohlsson L, Carlsson S, Wahlander K, Gustafsson D, Badimon JJ. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis. J Thromb Haemost 2003; 1: 999-1004.
18. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost 1995; 21 (Suppl. 2): 106-12.
19. Finkle CD, St Pierre A, Leblond L, Deschenes I, DiMaio J, Winocour PD. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis - comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost 1998; 79: 431-8.
20. Slack SM, Cui Y, Turitto VT. The effects of flow on blood coagulation and thrombosis. Thromb Haemost 1993; 70: 129-34.
21. Coller BS, Lang D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997; 95: 860-7.
22. Sakariassen KS, Nievelstein PF, Coller BS, Sixma JJ. The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol 1986; 63: 681-91.
23. Sixma JJ, Ijsseldijk MJ, Hindriks G, van Zanten GH, Gorecki M, Panet A, Garfinkel LI, de Groot PG. Adhesion of blood platelets is inhibited by VCL, a recombinant fragment (leucine504 to lysine728) of von Willebrand factor. Arterioscler Thromb Vasc Biol 1996; 16: 64-71.
24. Varon D, Lashevski I, Brenner B, Beyar R, Lanir N, Tamarin I, Savion N. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 1998; 135: S187-93.
25. Renda G, Rocca B, Crocchiolo R, Cristofaro RD, Landolfi R. Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban. Thromb Haemost 2003; 89: 348-54.
26. Kumar R, Beguin S, Hemker HC. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. Thromb Haemost 1995; 74: 962-8.
27. Diamond SL. Tissue factor activity under flow. Thromb Res 2010; 125 (Suppl. 1): S29-30.
28. Andre P, LaRocca T, Delaney SM, Lin PH, Vincent D, Sinha U, Conley PB, Phillips DR. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation 2003; 108: 2697-703.
29. Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, Uchiyama S, Gotoh J, Nagao T, Yamamoto M, Takahashi JC, Minematsu K. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke 2008; 39: 1740-5.
30. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, Renne C, Gailani D, Nieswandt B, Renne T. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-8.
31. Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 2507-13.
32. Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111: 4113-7.
33. Mackman N, Gruber A. Platelet polyphosphate: an endogenous activator of coagulation factor XII. J Thromb Haemost 2010; 8: 865-7.
34. Bossavy JP, Sakariassen KS, Thalamas C, Boneu B, Cadroy Y. Antithrombotic efficacy of the vitamin K antagonist fluindione in a human Ex vivo model of arterial thrombosis effect of anticoagulation level and combination therapy with aspirin. Arterioscler Thromb Vasc Biol 1999; 19: 2269-75.
35. Aird WC. Spatial and temporal dynamics of the endothelium. J Thromb Haemost 2005; 3: 1392-406.